425P - Clinical impact of [11C]-methionine positron emission tomography on the treatment of primary and recurrent gliomas

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Central Nervous System Malignancies
Staging procedures (clinical staging)
Basic Principles in the Management and Treatment (of cancer)
Presenter Matteo Santoni
Authors M. Santoni1, R. Berardi2, A. Bittoni2, A. Paccapelo3, C. Nanni4, S. Fanti5, L. Burattini2, S. Cascinu6
  • 1Clinica Di Oncologia Medica, AO Ospedali Riuniti, Università Politecnica delle Marche, Ancona/IT
  • 2Clinica Di Oncologia Medica, AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, 60126 - Ancona/IT
  • 3Medical Oncology, Ospedali Riuniti Torrette, 60126 - Ancona/IT
  • 4Department Of Nuclear Medicine, University of Bologna, Bologna/IT
  • 5Policlinico S.orsola, University of Bologna, Bologna/IT
  • 6Dipartimento Di Medicina Clinica E Biotecnologie A, AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, 60126 - Ancona/IT



To assess whether 11C-methionine positron emission tomography (11C-MET PET) has a clinical significance in the management of glioma patients.

Patients and methods

Fifty-three patients with histologically proven primary gliomas (16 grade II, 15 grade III, and 22 grade IV) were investigated repeatedly with 11C-MET PET. A total of 249 PET scans were performed, with a median of 4 scans for each patient. Functional imaging with PET was compared with concurrent MRI or CT.


We registered high sensibility and specificity in the management of glioma patients. The mean 11C-MET uptake index results significantly correlated with histological grade. The overall survival (OS) of GBM patients who underwent 11C-MET PET serial controls and parallel CT or MRI scans resulted to be 29.24 months, significantly higher compared to OS of GBM who underwent CT or MRI alone during follow up.


11C-MET PET allowed the detection of malignant progression in low grade glioma patients and the assessment of post-surgery status in both low and anaplastic gliomas with high sensibility and specificity. Thus, 11C-MET PET expresses its maximum potential in earlier disclosing recurrence during the long-term follow-up of GBM patients, with a relevant impact on therapeutic course and survival of these patients.


All authors have declared no conflicts of interest.